Crossbow Therapeutics
CT
CR
Crossbow Therapeutics
Agent45Agent Readiness: 45/100. Above median. Measured by StartupHub.ai. Median 41.Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.
About
Crossbow Therapeutics is a biotechnology company focused on developing novel T-cell receptor (TCR)-mimetic antibody therapies for the treatment of cancer. Their approach aims to leverage the specificity of T-cell receptors to target cancer cells with high precision. The company recently announced a $77 million Series B financing round to advance its pipeline.
Key facts
At-a-glance profile data
- Website
- crossbowtx.com
- Headquarters
- Cambridge, United States
- Founded
- 2021
- Employees
- 40
- Total funding
- $157M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 18 Mar 2026 | Series B | $77M | - |
| 11 Jul 2023 | Series A | $80M | Pfizer Ventures |
Tech stack
Detected on crossbowtx.com, last scanned 18 Sept 2026. Run your own scan
- Observability
- Sentry
- CMS / Builders
- Wix
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised a total of $157M in funding. The most recent round on record is Series B.
How many employees does Crossbow Therapeutics have?
Crossbow Therapeutics has approximately 40 people on record.